UnknownPhase 2NCT04718909

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC

Studying Adult hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Principal Investigator
Kangshun Zhu, Dr.
Second Affiliated Hospital of Guangzhou Medical University
Intervention
Regorafenib + sintilimab(drug)
Enrollment
166 enrolled
Eligibility
18-75 years · All sexes
Timeline
2021 – 2023

Study locations (1)

Collaborators

ZhuHai Hospital · Shenzhen People's Hospital · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Second Affiliated Hospital of Nanchang University · The First People's Hospital of Zhaoqing · Fifth Affiliated Hospital, Sun Yat-Sen University · Cancer Hospital of Guangxi Medical University · Jiangmen Central Hospital · Third Affiliated Hospital, Sun Yat-Sen University · Peking University Shenzhen Hospital · Jieyang People's Hospital · Shantou Central Hospital · Yuebei People's Hospital · Zhaoqing Gaoyao People's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04718909 on ClinicalTrials.gov

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adult hepatocellular carcinoma →

← Back to all trials